MTOR and leiomyosarcoma: Additionally, our group reported a clinical case of a uterine leiomyosarcoma patient who experienced stable disease for 30 months when treated with trabectedin; however, the most remarkable fact is that this patient, before starting trabectedin treatment, was treated within a clinical trial with the mTOR inhibitor ridaforolimus until progression [56].